The Future of Psychedelic Medicine
Novamind CMO Reid Robison speaks with Technology Networks about the growing interest in psychedelic medicine and what that could mean for the future of mental health.
Novamind Expands Footprint of Psychedelic Clinics
Our CEO Yaron Conforti and CMO Reid Robison discuss the news of our clinic expansion and how this further develops our model for scaling across the U.S.
How Modern Psychedelics Began with a Bike Ride
On April 19, 1943, chemist Albert Hofmann took .00005 teaspoons of LSD. As he rode his bicycle home, he realized that the world had just changed. By Novamind CMO, Dr. Reid Robison and Kirsten Hirst.
Pierre Bou-Mansour Discusses the Initial Phase of Novamind’s National Expansion Strategy
Our Chief Operating Officer speaks with the Wall Street Reporter about our clinic expansion, the key drivers of our growth, and the importance of set and setting in our clinics.
Why Merck Chose Novamind to Lead a Groundbreaking Study
Our CEO and CMO spoke with Streetwise Reports about how Cedar Clinical Research is positioned to develop a new option for treatment-resistant depression.
Dr. Reid Robison on the Science of Psychedelics
Leafly interviews Novamind’s CMO about how these compounds influence our mind on a molecular level.